Louisiana State Employees Retirement System Has $3.84 Million Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Louisiana State Employees Retirement System boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 0.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 28,100 shares of the company’s stock after buying an additional 100 shares during the quarter. Louisiana State Employees Retirement System’s holdings in Neurocrine Biosciences were worth $3,836,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of NBIX. Cetera Investment Advisers lifted its holdings in Neurocrine Biosciences by 7.9% during the 2nd quarter. Cetera Investment Advisers now owns 7,112 shares of the company’s stock worth $979,000 after buying an additional 519 shares in the last quarter. Sanctuary Advisors LLC acquired a new position in Neurocrine Biosciences during the 2nd quarter worth $510,000. CWM LLC lifted its holdings in Neurocrine Biosciences by 15.1% during the 3rd quarter. CWM LLC now owns 7,884 shares of the company’s stock worth $908,000 after buying an additional 1,035 shares in the last quarter. Exchange Traded Concepts LLC raised its position in shares of Neurocrine Biosciences by 29.3% during the 3rd quarter. Exchange Traded Concepts LLC now owns 7,964 shares of the company’s stock valued at $918,000 after acquiring an additional 1,803 shares during the last quarter. Finally, Creative Planning raised its position in shares of Neurocrine Biosciences by 12.3% during the 3rd quarter. Creative Planning now owns 12,999 shares of the company’s stock valued at $1,498,000 after acquiring an additional 1,426 shares during the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on NBIX. Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a research report on Friday, February 7th. Deutsche Bank Aktiengesellschaft began coverage on shares of Neurocrine Biosciences in a research report on Tuesday. They set a “hold” rating and a $138.00 target price for the company. Wedbush dropped their target price on shares of Neurocrine Biosciences from $157.00 to $147.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. StockNews.com upgraded shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Monday. Finally, HC Wainwright dropped their target price on shares of Neurocrine Biosciences from $190.00 to $185.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Five research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $166.90.

Neurocrine Biosciences Trading Up 0.3 %

NBIX stock opened at $117.18 on Thursday. The stock has a 50-day moving average price of $138.49 and a two-hundred day moving average price of $131.02. The stock has a market cap of $11.86 billion, a PE ratio of 35.62 and a beta of 0.33. Neurocrine Biosciences, Inc. has a 1 year low of $110.95 and a 1 year high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.45% and a net margin of 14.49%. On average, analysts forecast that Neurocrine Biosciences, Inc. will post 6.53 earnings per share for the current fiscal year.

Insider Transactions at Neurocrine Biosciences

In other news, CEO Kyle Gano sold 980 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $118.39, for a total transaction of $116,022.20. Following the completion of the transaction, the chief executive officer now directly owns 137,658 shares in the company, valued at $16,297,330.62. This represents a 0.71 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Ingrid Delaet sold 1,091 shares of the stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $135.00, for a total transaction of $147,285.00. Following the transaction, the insider now owns 2,507 shares of the company’s stock, valued at approximately $338,445. This represents a 30.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 226,647 shares of company stock worth $33,186,271 in the last three months. Insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.